Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.

Pal, Sumanta Kumar; Tannir, Nizar M.; Grell, Peter; Gao, Xin; Kotecha, Ritesh R; Picus, Joel; De Braud, Filippo G.; Takahashi, Shunji; Wong, Alvin; Suárez, Cristina; Otero, Javier A; Kundamal, Nicole; Yang, Xin; Sharaby, Sherif; Roy, Mike; Barzaghi-Rinaudo, Patrizia; Albiges, Laurence

doi:10.1200/jco.2024.42.16_suppl.4513

Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.

4513 Background: Targeting HIF2α inhibition has been proven to be an effective therapeutic option in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC). DFF332, a small molecule inhibitor that selectively targets HIF2α transcriptional activity, has shown dose-dependent antitumor…